Anaplastic Astrocytoma - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 130 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Astrocytoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Anaplastic Astrocytoma - Pipeline Review, H2 2015', provides an overview of the Anaplastic Astrocytoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Astrocytoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anaplastic Astrocytoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anaplastic Astrocytoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Astrocytoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Anaplastic Astrocytoma Overview 9
Therapeutics Development 10
Pipeline Products for Anaplastic Astrocytoma - Overview 10
Pipeline Products for Anaplastic Astrocytoma - Comparative Analysis 11
Anaplastic Astrocytoma - Therapeutics under Development by Companies 12
Anaplastic Astrocytoma - Therapeutics under Investigation by Universities/Institutes 14
Anaplastic Astrocytoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Anaplastic Astrocytoma - Products under Development by Companies 18
Anaplastic Astrocytoma - Products under Investigation by Universities/Institutes 19
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 20
Aduro BioTech, Inc. 20
Amgen Inc. 21
Axelar AB 22
Boehringer Ingelheim GmbH 23
Burzynski Research Institute, Inc. 24
Cavion LLC 25
Celldex Therapeutics, Inc. 26
e-Therapeutics Plc 27
Eli Lilly and Company 28
Millennium Pharmaceuticals, Inc. 29
Novartis AG 30
Orbus Therapeutics, Inc. 31
Pfizer Inc. 32
Sanofi 33
Tocagen Inc. 34
TVAX Biomedical, Inc. 35
Anaplastic Astrocytoma - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ADU-623 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
afatinib dimaleate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
alisertib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AMG-595 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Antineoplaston Therapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AXL-1717 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CDX-1401 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Dendritic Cell Therapy for Gliomas - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Dendritic Cell Therapy for Oncology - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DNX-2401 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
eflornithine hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ETS-2101 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
flucytosine + TBio-01 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
galunisertib - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
irinotecan hydrochloride + TBio-02 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
mibefradil dihydrochloride - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
nilotinib - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
palbociclib - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
plerixafor - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
temsirolimus - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TVI-Brain-1 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
vocimagene amiretrorepvec + flucytosine ER - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Anaplastic Astrocytoma - Recent Pipeline Updates 96
Anaplastic Astrocytoma - Dormant Projects 126
Anaplastic Astrocytoma - Discontinued Products 127
Anaplastic Astrocytoma - Product Development Milestones 128
Featured News & Press Releases 128
Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 128
Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 129
Disclaimer 130

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, H2 2015 10
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Investigation by Universities/Institutes, H2 2015 19
Anaplastic Astrocytoma - Pipeline by Aduro BioTech, Inc., H2 2015 20
Anaplastic Astrocytoma - Pipeline by Amgen Inc., H2 2015 21
Anaplastic Astrocytoma - Pipeline by Axelar AB, H2 2015 22
Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 23
Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H2 2015 24
Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2015 25
Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics, Inc., H2 2015 26
Anaplastic Astrocytoma - Pipeline by e-Therapeutics Plc, H2 2015 27
Anaplastic Astrocytoma - Pipeline by Eli Lilly and Company, H2 2015 28
Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 29
Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2015 30
Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H2 2015 31
Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H2 2015 32
Anaplastic Astrocytoma - Pipeline by Sanofi, H2 2015 33
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H2 2015 34
Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H2 2015 35
Assessment by Monotherapy Products, H2 2015 36
Assessment by Combination Products, H2 2015 37
Number of Products by Stage and Target, H2 2015 39
Number of Products by Stage and Mechanism of Action, H2 2015 41
Number of Products by Stage and Route of Administration, H2 2015 43
Number of Products by Stage and Molecule Type, H2 2015 45
Anaplastic Astrocytoma Therapeutics - Recent Pipeline Updates, H2 2015 96
Anaplastic Astrocytoma - Dormant Projects, H2 2015 126
Anaplastic Astrocytoma - Discontinued Products, H2 2015 127